Tumor Biology

, Volume 31, Issue 1, pp 8–15 | Cite as

Clinicopathologic prognostic markers of survival: an analysis of 259 patients with malignant melanoma ≥1 mm

  • Friederike Egberts
  • A. Momkvist
  • J. H. Egberts
  • K. C. Kaehler
  • M. Weichenthal
  • A. Hauschild
Research Article

Abstract

The histopathologic status of the sentinel node (SN) and the ulceration of the primary tumor are important indicators of the clinical outcome of melanoma patients. The purpose of this study was to investigate potential correlations between prognostic factors and the sentinel lymph node status as well as their influence on disease-free survival (DFS), distant metastases-free survival (DMFS), and overall survival (OS). The medical records of 259 melanoma patients who underwent sentinel lymph node dissection between 2000 and 2006 were analyzed. DFS, DMFS, and OS were assessed. A uni- and a multivariate analysis to determine prognostic factors were performed. Histologic type, Clark’s level, and Breslow’s tumor thickness were the only parameters that showed a significant correlation with a positive SN. The univariate analysis revealed SN positivity (DFS and DMFS: p < 0.001; OS: p = 0.039) and ulceration (DFS: p < 0.001; DMFS: p = 0.001; OS: p = 0.003) to be significant prognostic markers. However, ulceration was the only independent prognostic factor for OS that was upheld by the multivariate analysis (p = 0.006; HR 3.89; CI 1.48–10.27). In stage I/II melanoma patients, ulceration of the primary tumor was the strongest prognostic factor for RFS, DMFS, and OS and superior to the pathology status of the SN.

Keywords

Melanoma Sentinel node Ulceration Prognosis Metastasis 

Notes

Acknowledgments

We thank Ulrike Schulz, Medistat, Kiel, Germany, for her substantial impact to the statistics in the study.

References

  1. 1.
    Morton DL, Wen DR, Foshag LJ, Essner R, Cochran A. Intraoperative lymphatic mapping and selective cervical lymphadenectomy for early-stage melanomas of the head and neck. J Clin Oncol. 1993;11:1751–6.PubMedGoogle Scholar
  2. 2.
    Medalie N, Ackerman AB. Sentinel node biopsy has no benefit for patients whose primary cutaneous melanoma has metastasized to a lymph node and therefore should be abandoned now. Br J Dermatol. 2004;151:298–307.CrossRefPubMedGoogle Scholar
  3. 3.
    Mohrle M, Schippert W, Rassner G, Garbe C, Breuninger H. Is sentinel lymph node biopsy of therapeutic relevance for melanoma? Dermatology. 2004;209:5–13.CrossRefPubMedGoogle Scholar
  4. 4.
    Mohrle M, Breuninger H. Sentinel node biopsy. What are the facts? Hautarzt. 2005;56:441–7.CrossRefPubMedGoogle Scholar
  5. 5.
    Perrott RE, Glass LF, Reintgen DS, Fenske NA. Reassessing the role of lymphatic mapping and sentinel lymphadenectomy in the management of cutaneous malignant melanoma. J Am Acad Dermatol. 2003;49:567–88. quiz 589-592.CrossRefPubMedGoogle Scholar
  6. 6.
    Roberts DL, Anstey AV, Barlow RJ, Cox NH, Newton Bishop JA, Corrie PG, et al. U.K. guidelines for the management of cutaneous melanoma. Br J Dermatol. 2002;146:7–17.CrossRefPubMedGoogle Scholar
  7. 7.
    Morton DL, Thompson JF, Cochran AJ, Mozzillo N, Elashoff R, Essner R, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med. 2006;355:1307–17.CrossRefPubMedGoogle Scholar
  8. 8.
    Gershenwald JE, Thompson W, Mansfield PF, Lee JE, Colome MI, Tseng CH, et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol. 1999;17:976–83.PubMedGoogle Scholar
  9. 9.
    Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, et al. Final version of the American Joint Committee on cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19:3635–48.PubMedGoogle Scholar
  10. 10.
    van Akkooi AC, de Wilt JH, Verhoef C, Graveland WJ, van Geel AN, Kliffen M, et al. High positive sentinel node identification rate by EORTC melanoma group protocol. Prognostic indicators of metastatic patterns after sentinel node biopsy in melanoma. Eur J Cancer. 2006;42:372–80.CrossRefPubMedGoogle Scholar
  11. 11.
    Yee VS, Thompson JF, McKinnon JG, Scolyer RA, Li LX, McCarthy WH, et al. Outcome in 846 cutaneous melanoma patients from a single center after a negative sentinel node biopsy. Ann Surg Oncol. 2005;12:429–39.CrossRefPubMedGoogle Scholar
  12. 12.
    Roka F, Kittler H, Cauzig P, Hoeller C, Hinterhuber G, Wolff K, et al. Sentinel node status in melanoma patients is not predictive for overall survival upon multivariate analysis. Br J Cancer. 2005;92:662–7.CrossRefPubMedGoogle Scholar
  13. 13.
    Eigentler TK, Caroli UM, Radny P, Garbe C. Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. Lancet Oncol. 2003;4:748–59.CrossRefPubMedGoogle Scholar
  14. 14.
    Garbe C, Hauschild A, Volkenandt M, Schadendorf D, Stolz W, Reinhold U, et al. Evidence and interdisciplinary consensus-based German guidelines: surgical treatment and radiotherapy of melanoma. Melanoma Res. 2008;18:61–7.CrossRefPubMedGoogle Scholar
  15. 15.
    Thomas JM, Clark MA. Selective lymphadenectomy in sentinel node-positive patients may increase the risk of local/in-transit recurrence in malignant melanoma. Eur J Surg Oncol. 2004;30:686–91.CrossRefPubMedGoogle Scholar
  16. 16.
    Kretschmer L, Hilgers R, Mohrle M, Balda BR, Breuninger H, Konz B, et al. Patients with lymphatic metastasis of cutaneous malignant melanoma benefit from sentinel lymphonodectomy and early excision of their nodal disease. Eur J Cancer. 2004;40:212–8.CrossRefPubMedGoogle Scholar
  17. 17.
    Twomey P. Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in mslt-1, an international multicenter trial. Ann Surg. 2007;245:156–7.CrossRefPubMedGoogle Scholar
  18. 18.
    Morton DL, Cochran AJ, Thompson JF. Authors' response to a letter to the editor re: sentinel node biopsy for early-stage melanoma. Ann Surg. 2007;245:828–9.CrossRefPubMedGoogle Scholar
  19. 19.
    Thomas JM. Time to re-evaluate sentinel node biopsy in melanoma post-multicenter selective lymphadenectomy trial. J Clin Oncol. 2005;23:9443–4.CrossRefPubMedGoogle Scholar
  20. 20.
    van Akkooi AC, de Wilt JH, Verhoef C, Schmitz PI, van Geel AN, Eggermont AM, et al. Clinical relevance of melanoma micrometastases (<0.1 mm) in sentinel nodes: are these nodes to be considered negative? Ann Oncol. 2006;17:1578–85.CrossRefPubMedGoogle Scholar
  21. 21.
    Eggermont AM, Suciu S, Santinami M, Testori A, Kruit WH, Marsden J, et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet. 2008;372:117–26.CrossRefPubMedGoogle Scholar
  22. 22.
    Ostmeier H, Fuchs B, Otto F, Mawick R, Lippold A, Krieg V, et al. Can immunohistochemical markers and mitotic rate improve prognostic precision in patients with primary melanoma? Cancer. 1999;85:2391–9.CrossRefPubMedGoogle Scholar
  23. 23.
    Zogakis TG, Essner R, Wang HJ, Foshag LJ, Morton DL. Natural history of melanoma in 773 patients with tumor-negative sentinel lymph nodes. Ann Surg Oncol. 2007;14:1604–11.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2009

Authors and Affiliations

  • Friederike Egberts
    • 1
  • A. Momkvist
    • 1
  • J. H. Egberts
    • 2
  • K. C. Kaehler
    • 1
  • M. Weichenthal
    • 1
  • A. Hauschild
    • 1
  1. 1.Department of DermatologySchleswig-Holstein University Hospital, Campus KielKielGermany
  2. 2.Department of General and Thoracic SurgerySchleswig-Holstein University Hospital, Campus KielKielGermany

Personalised recommendations